aTyr Pharma (ATYR) Stock Analysis & Winston Score

aTyr Pharma is a small biotechnology company focused on discovering and developing medicines for rare diseases. Its main work centers on a class of proteins called aminoacyl-tRNA synthetases, which the company believes can be turned into drugs that calm overactive immune responses. Its lead drug candidate, efzofitimod, is being tested in patients with a rare lung disease called pulmonary sarcoidosis.

The company earns almost no revenue today and funds its operations primarily through stock offerings and partnerships, which is typical for early-stage biotech firms. aTyr is based in San Diego, California, and operates entirely in the United States at this stage of development. The deeply negative margins reflect the reality that it is spending heavily on clinical trials without yet selling an approved product. The biggest risk the company faces is whether efzofitimod will succeed in late-stage clinical trials, since a failed trial would severely threaten its ability to continue operating.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+22.2% YoY

YoY Growth Rate

Steady EPS growth

Insider Activity

2.6%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~3 months

$11M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

aTyr Pharma has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-21.5%

Weak — -21.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-19.1%

Shrinking sales (-19.1% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-32664.7%

Burning cash (-32664.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.02

Conservative — low debt load (0.02)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial